# The EndoSound® Newsletter | EndoSound

- Canonical URL: https://wefunder.com/feed/338156
- Entity ID: wefunder:feed_item:338156
- Published at: 2026-06-17 15:27:20 UTC
- Updated at: 2026-06-21 04:12:01 UTC

## Author
Patrick Hurley

## Subject
EndoSound

## Content
As we progress through what has been a busy May and June, we wanted to take a moment to share several important milestones that continue to reinforce our confidence in EndoSound's future and the tremendous opportunity ahead of us.EVS® Gen 2 Receives Strong FeedbackWe were fortunate to have two experienced EndoSound® users evaluate the EVS® Gen 2 immediately following the meeting, and their feedback was overwhelmingly positive.Both physicians noted substantial improvements in navigation, image quality, workflow integration, and overall performance. Most importantly, they recognized that the enhancements incorporated into the new platform directly addressed feedback gathered from real-world clinical use of our first-generation system.For our team, this validation is especially meaningful. Countless hours of engineering, product development, and customer engagement have culminated in a product that is being well received by both supporters and critics of the original system.First New User Evaluation of Gen 2We conducted our first evaluation with a physician who had never previously used the EndoSound EVS.The physician's experience was promising and further supports what we have believed from the beginning: when clinicians use the technology firsthand, they quickly recognize its potential value in their practice. We are hopeful that this evaluation will result in our first domestic PO from a new user for the EVS Gen 2.As we continue evaluations for additional sites, we look forward to converting this momentum into broader clinical adoption.Impressive Momentum Across Latin AmericaDDW highlighted the buzz about EndoSound in both the United States and abroad. We are equally motivated by the advancement in Latin America (LATAM).We are pleased to report that these efforts translated into more than $400,000 in purchase orders from our distributor partners across Latin America. These orders were the direct result of commercial and clinical efforts to introduce the new platform to physicians and healthcare facilities across the region. This represents an important milestone for the company and provides further validation of the commercial opportunity for the EVS.Just as importantly, demand throughout the region continues to grow. Our distributor network remains highly engaged, and regulatory filings are actively progressing in multiple countries to support broader market access and future expansion.Looking AheadThe progress achieved represents much more than a successful conference or strong sales activity. It reflects growing physician confidence, increasing market awareness, and the successful execution of our strategy across both domestic and international markets.With the launch of the EVS Gen 2, expanding physician evaluations, growing international demand, and a strengthening commercial pipeline, we believe EndoSound is entering one of the most exciting periods in the company's history.Thank you for your continued support, confidence, and belief in our mission. We remain committed to advancing endoscopic ultrasound through innovation while creating long-term value for our customers, partners, and investors.Sincerely,The EndoSound Team